Publications and presentations

AVEO Oncology allows you to access a number of published papers and presentations outlining our clinical data that were given at premier conferences and symposia around the world.

September 1, 2021
PublicationFiclatuzumab

Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis

Authors: Victoria E. Wang, Bradley W. Blaser, Ravi K. Patel, Gregory K. Behbehani, Arjun A. Rao, Blythe Durbin-Johnson, Tommy Jiang, Aaron C. Logan, Matthew Settles, Gabriel N. Mannis, Rebecca Olin, Lloyd E. Damon, Thomas G. Martin, Peter H. Sayre, Karin M. Gaensler, Emma McMahon, Michael Flanders, Vivian Weinberg, Chun J. Ye, David P. Carbone, Pamela N. Munster, Gabriela K. Fragiadakis, Frank McCormick, Charalambos Andreadis. Click here for link to article.

June 4, 2021
PresentationFiclatuzumab

ASCO 2021: Randomized Phase II Trial of Ficlatuzumab with or without Cetuximab in Pan-Refractory, Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

June 4, 2021
PresentationTivozanib

ASCO 2021: TIVO-3: Durability of Response and Updated Overall Survival of Tivozanib vs Sorafenib in Metastatic Renal Cell Carcinoma (mRCC)

June 4, 2021
PresentationTivozanib

ASCO 2021: Temporal Characteristics of Treatment-Emergent Adverse Events and Dose Modifications With Tivozanib and Sorafenib in the Phase 3 TIVO-3 Study of Relapsed or Refractory mRCC

February 11, 2021
PresentationTivozanib

ASGO GU 2021: Q-TWiST analysis of tivozanib versus sorafenib in patients with advanced renal cell carcinoma (RCC) in the TIVO-3 study

February 11, 2021
PresentationTivozanib

ASCO GU 2021: Tivozanib in Patients with Advanced Renal Cell Carcinoma (aRCC) who have Progressed After Prior Treatment with Axitinib: Results from TIVO-3

1 2 3 4 5 6 … 14

Looking for medical information? Contact our Medical Information Team at

AVEOmedicalinformation@aveooncology.com.